Propio Achieves HITRUST e1 Certification Demonstrating Foundational Cybersecurity
OVERLAND PARK, KS / ACCESS Newswire / March 4, 2025 / Propio, an industry-leading language solutions partner powered by advanced technology, announced that its web-based platform, Propio ONE, supporting video, audio, and on-site interpretation, along with its comprehensive resource management platform, WorkforceOS, have both earned certified status by HITRUST for foundational cybersecurity.
HITRUST e1 Certification demonstrates Propio is focused on the most critical controls to showcase essential cybersecurity hygiene is in place. The e1 assessment is one of three progressive HITRUST assessments leveraging the HITRUST Framework (HITRUST CSF) to prescribe adaptive cyber threat controls appropriate for each assurance level.
'There's no room for mismanagement of information because there's no tolerance for mistrust from our clients. We have to prove to our clients day in and day out that we can stay ahead of emerging threats. HITRUST e1 Certification is a great way to show our commitment to cybersecurity and data protection,' said Donnie Dooley, Propio's Chief Technology Officer.
'The HITRUST e1 Validated Assessment is a good tool for cyber-aware organizations like Propio that want to build assurances and progressively demonstrate due diligence around information security and privacy,' said Robert Booker, Chief Strategy Officer at HITRUST. 'We applaud Propio for their commitment to cybersecurity and successful completion of their HITRUST e1 Certification.'
About Propio
Propio is an industry-leading language and technology solutions partner serving over 12,000 regional and national clients. Powered by advanced technology and guided by a vision to 'eliminate the everyday obstacles of communication,' Propio offers a robust suite of services-including video, phone, and on-site interpretation in 300 languages, as well as translation and localization solutions tailored for a range of industries, including healthcare, education, legal, and financial. Additionally, Propio offers WorkforceOS, an end-to-end resource management platform, that can help increase healthcare access and improve healthcare equity. Recognized as one of the fastest-growing language services companies, Propio continues to set industry standards with its innovative solutions.Propio media contact: Sarah Haner, VP MarketingSOURCE: Propio LS, LLC.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 hours ago
- Yahoo
Vertical Aerospace Expands Leadership Team With Key Executive Appointments
Mark Higson joins as Chief Operating Officer, Steve Vellacott joins as VP, Airworthiness & Head of Design Organisation, and Eric Samson named VP Programme-Hybrid Strengthened leadership team will support operational, commercial, and technological advancements as Vertical accelerates towards global certification and commercialisation LONDON & NEW YORK, July 03, 2025--(BUSINESS WIRE)--Vertical Aerospace (Vertical) [NYSE: EVTL], a global aerospace and technology company that is pioneering electric aviation, today announced the addition of key executives to its leadership team as the Company accelerates through its Flightpath 2030 goals. Stuart Simpson, CEO of Vertical Aerospace, said: "These appointments further reinforce our leadership bench as we accelerate into our next phase of growth and global deployment. Mark and Steve bring decades of deep operational and engineering expertise that will be instrumental in driving the certification and commercialisation of the VX4 at scale. Eric's focused leadership, technical insight, and deep certification experience will be invaluable as we advance our hybrid-electric VX4 strategy and expand our market potential." Mark Higson joins as Chief Operating Officer and is a seasoned executive with significant expertise in developing operational and commercial strategies, leading complex, global organisations through transformational change. He has over four decades of experience across international businesses, most recently serving as Chief Executive Officer of Modulaire Group, a global leader in modular services and infrastructure, where he successfully led the sale and refinancing of the business. Originally an Aerospace Engineer, Mark started his career at British Aerospace subsequently serving in senior operational leadership roles across the industrials sector, including at Wolseley UK and the Royal Mail, and as a senior advisor to McKinsey & Company and to Advent International's portfolio companies. Steve Vellacott joins as VP of Airworthiness & Head of Design Organisation, bringing decades of experience in structural engineering and design, including significant expertise leading electric and other complex VTOL programmes. He joins Vertical from Lilium where he was Chief Technology Officer and Head of Design, overseeing the team responsible for the design, development and certification of its eVTOL aircraft. Prior to Lilium, Steve spent over three decades at Leonardo Helicopters, holding a variety of leadership roles across its international civil and military programmes, where he worked closely with EASA around certification and compliance of the aircraft. He was elected as a Fellow of the Royal Aeronautical Society in 2018. Eric Samson named as VP Programme-Hybrid, building on the Company's recently announced hybrid-electric VTOL aircraft strategy. Eric is a proven aerospace leader with extensive experience in aircraft design and systems integration. Since joining Vertical in 2020, he has served as Senior Vice President of Engineering and Head of Design Organisation, leading Vertical's Engineering and Design Organisation to design, build, test and prepare to certify the VX4 . Prior to Vertical, Eric held various technical and leadership roles, including at Jet Aviation and Gulfstream Aerospace. The expansion of Vertical's leadership team builds on the Company's significant momentum and progress towards delivering a scalable, certifiable aircraft to the global market. Vertical remains on track to complete its test flight program in 2025, having recently achieved the first piloted wingborne flight of a winged eVTOL in European public airspace. About Vertical Aerospace Vertical Aerospace is a global aerospace and technology company pioneering electric aviation. Vertical is creating a safer, cleaner and quieter way to travel. Vertical's VX4 is a piloted, four passenger, Electric Vertical Take-Off and Landing (eVTOL) aircraft, with zero operating emissions. Vertical will also be launching a hybrid-electric variant, offering increased range and mission flexibility to meet the evolving needs of the advanced air mobility market. Vertical combines partnering with leading aerospace companies, including GKN, Honeywell and Leonardo, with developing its own proprietary battery and propeller technology to develop the world's most advanced and safest eVTOL. Vertical has c.1,500 pre-orders of the VX4, with customers across four continents, including American Airlines, Japan Airlines, GOL and Bristow. Certain customer obligations are expected to be fulfilled via third-party agreements. Headquartered in Bristol, the epicentre of the UK's aerospace industry, Vertical's experienced leadership team comes from top tier automotive and aerospace companies such as Rolls-Royce, Airbus, GM and Leonardo. Together they have previously certified and supported over 30 different civil and military aircraft and propulsion systems. Forward-Looking Statements This Press Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that relate to our current expectations and views of future events. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements as contained in Section 27A of the Securities Act and 21E of the Exchange Act. Any express or implied statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation, statements regarding anticipated leadership changes and their impact on Vertical and its certification and commercialization efforts, the design and manufacture and the features and capabilities of the VX4 and the hybrid-electric variant, business strategy and plans and objectives of management for future operations, including the building and testing of our prototype aircrafts on timelines projected, completion of the piloted test programme phases, selection of suppliers, certification and the commercialization of the VX4 and the hybrid-electric variant and our ability to achieve regulatory certification of our aircraft product on any particular timeline or at all, expectations surrounding pre-orders and commitments, the transition towards a net-zero emissions economy, our future results of operations and financial position and expected financial performance and operational performance, liquidity, growth and profitability strategies, business strategy and plans and objectives of management for future operations, our ability and plans to raise additional capital to fund our operations, our plans to mitigate the risk that we are unable to continue as a going concern, our plans for capital expenditures, as well as statements that include the words "expect," "intend," "plan," "believe," "project," "forecast," "estimate," "may," "should," "anticipate," "will," "aim," "potential," "continue," "is/are likely to" and similar statements of a future or forward-looking nature. These forward-looking statements reflect our current views with respect to future events and are not a guarantee of future performance. Actual outcomes may differ materially from the information contained in the forward-looking statements as a result of a number of factors, including, without limitation, the important factors discussed under the caption "Risk Factors" in the Company's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC") on March 11, 2025, as such factors may be updated from time to time in the Company's other filings with the SEC. Any forward-looking statements contained in this release speak only as of the date hereof and accordingly undue reliance should not be placed on such statements. the Company disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this release whether as a result of new information, future events or otherwise, other than to the extent required by applicable law. View source version on Contacts For more information:Justin Bates, Head of Communications +44 7878 357 463Samuel Emden, Head of Investor Affairs +447816 459 904 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
20 hours ago
- Associated Press
Propio Language Services Acquires CyraCom, Combining Two of the World's Largest Healthcare Interpretation Providers
OVERLAND PARK, KS / ACCESS Newswire / July 3, 2025 / Propio, a leading innovator in interpreting, translation, and localization solutions, is proud to announce its acquisition of CyraCom International Inc., one of the world's largest remote interpretation providers that specializes in healthcare. This historic transaction brings together two of the largest U.S.-based Language Service Providers (LSPs), creating an unparalleled partnership capable of delivering expanded solutions, deeper expertise, and even greater resources to clients across healthcare, government, insurance, education and enterprise sectors. 'This is a transformative moment in our industry and Propio is taking the lead in it,' said Marco Assis, CEO of Propio. 'We are combining two trusted leaders with decades of remote-interpretation excellence. Together, we'll set an even greater standard for access, speed, and quality in language solutions.' Clients of both organizations will benefit from a seamless transition, continued support from their dedicated teams, and immediate access to enhanced technology and service options. The combined entity will allow for Propio's AI-powered automation and workflows, technology solutions, and compliance infrastructure, to drive even better outcomes for the new clients and the communities they serve. 'Language access is something both organizations are very passionate about and, together, we will be able to more effectively help our clients remove barriers to communication and care,' added Assis. The integration process is already underway, with both leadership teams working closely to ensure a smooth and transparent experience for all clients. About Propio Language Services Propio is an industry-leading language solutions partner that combines high-quality human expertise with advanced technology to support interpretation, translation, and localization needs across healthcare, education, legal, financial, and other industries. To support its clients, Propio offers secure, easy-to-use tools like the Propio ONE app for interpretation, Propio Workforce OS® for resource service coordination in healthcare, and AI translation solutions to increase speed and efficiency. Powered by a network of over 20,000 linguists covering 300+ languages, Propio now works with more than 12,000 client partners worldwide. Propio's vision is simple: to make communication easier through the use of advanced technology. About CyraCom CyraCom has been a leader in language services for over 30 years, specializing in over-the-phone and video interpretation. Known for its rigorous interpreter training and U.S.-based operations, CyraCom has supported clients across healthcare, legal, and public service industries. Media Contact: Sarah Haner, Marketing Director [email protected] SOURCE: Propio Language Services press release
Miami Herald
20 hours ago
- Miami Herald
MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks
With Mira-55 and Ketamir-2, MIRA is advancing complementary non-opioid therapies for two of the largest pain markets MIAMI, FLORIDA / ACCESS Newswire / July 3, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced positive preclinical data demonstrating that Mira-55, the Company's proprietary non-psychotropic marijuana analog, delivered morphine-comparable pain relief in a validated model of inflammatory pain-without causing local inflammation. Mira-55 is a next-generation analog of marijuana, engineered to selectively activate CB2 cannabinoid receptors, which are associated with anti-inflammatory and analgesic effects. Unlike THC, Mira-55 minimizes activation of CB1 receptors, reducing the risk of euphoria, sedation, and pro-inflammatory side effects. "These results reinforce the value of Mira-55 as a differentiated cannabinoid-based therapy with real clinical potential," said Erez Aminov, Chairman and CEO of MIRA. "We believe the drug's ability to match morphine's pain relief-without the baggage of addiction, sedation, or THC-like effects-makes Mira-55 an ideal candidate for large, underserved inflammatory pain markets. It's another step in building a non-opioid pain franchise that addresses both inflammatory and neuropathic pain." Study Overview and Key Findings Mira-55 was tested using the formalin model, a gold-standard preclinical method for studying inflammatory pain. In this model, formalin is injected into the rat's paw, producing a pain response that mimics human inflammatory pain. Pain sensitivity was assessed using Von Frey Filament testing, which measures tactile pain thresholds, and inflammation was measured by paw edema volume. Key findings: Mira-55 reduced pain sensitivity by approximately threefold, restoring thresholds to near-baseline analgesic effect was equivalent to morphine, the standard opioid comparator in the sedation or inflammatory swelling was observed with Mira-55 treatment. Importantly, following a scientific review, the U.S. Drug Enforcement Administration (DEA) determined that Mira-55 is not classified as a controlled substance. This designation supports the compound's long-term clinical and commercial viability and removes key barriers typically associated with cannabinoid-based drug development. These results build on prior data from a separate inflammatory pain model conducted by a leading U.S. academic research center, where Mira-55 blocked both thermal and mechanical hyperalgesia without increasing inflammation. In contrast, low-dose THC in that model exacerbated inflammation-further validating Mira-55's selective pharmacological profile. "Mira-55 offers the pain-relieving potential of cannabinoids without the liabilities traditionally seen in THC-based drugs," said Dr. Itzchak Angel, Chief Scientific Advisor at MIRA. "Its novel structure and unique profile with CB2 selectivity and non-scheduled DEA status make it a compelling candidate for treating inflammation-driven pain conditions that are poorly managed by today's standards." Strategic Fit Within MIRA's Pain Portfolio Mira-55 complements Ketamir-2, MIRA's clinical-stage NMDA receptor antagonist, which is advancing through Phase 1 development for neuropathic pain. While Ketamir-2 addresses nerve-related pain through central mechanisms, Mira-55 targets inflammatory pain through the endocannabinoid system. Together, they represent two mechanistically distinct, non-opioid approaches to treating chronic pain. "With Mira-55 and Ketamir-2, we now have two highly differentiated drug candidates with the potential to transform how inflammatory and neuropathic conditions are treated," added Aminov. "We're advancing each asset methodically, and we're energized by the momentum we've built across the pipeline." Corporate Update on SKNY Merger MIRA also announced continued progress on its previously disclosed acquisition of SKNY Pharmaceuticals, the developer of SKNY-1, a novel investigational therapy targeting both obesity and nicotine addiction. In recent studies, SKNY-1 demonstrated a 30% reduction in body weight without muscle loss, along with a reversal of nicotine cravings-highlighting its potential as a differentiated treatment in two major markets. The U.S. Securities and Exchange Commission (SEC) has completed its review of the merger proxy with no comments, allowing MIRA to proceed with shareholder approval and the final steps toward completing the transaction. "We are pleased to report that the SEC had no comments on our merger filing, which reflects the quality of our regulatory and business preparation," said Aminov. "This milestone allows us to advance toward shareholder approval with clarity and confidence as we prepare for the next phase of growth." Next Steps MIRA Pharmaceuticals is advancing Mira-55 toward an Investigational New Drug (IND) submission, with ongoing activities supporting future clinical development in inflammatory pain. The Company remains focused on progressing both lead programs-Mira-55 and Ketamir-2-toward their next regulatory and clinical milestones. About MIRA Pharmaceuticals, Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in areas such as neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. Cautionary Note Regarding Forward-Looking StatementsThis press release and the statements of MIRA's management related thereto contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA's current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA's potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA's programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 14A filed by MIRA on June 18, 2025, and other SEC filings, which are on file with the SEC at and on MIRA's website at MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact:Helga Moyainfo@ 432-9792 SOURCE: MIRA Pharmaceuticals
